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Reduction in levels of sex hormones at menopause in women
is associated with two common,major outcomes, the accumula-
tion of white adipose tissue, and the progressive loss of bone
because of excess osteoclastic bone resorption exceeding osteo-
blastic bone formation. Current antiresorptive therapies can
reduce osteoclastic activity but have only limited capacity to
stimulate osteoblastic bone formation and restore lost skeletal
mass. Likewise, the availability of effective pharmacological
weight loss treatments is currently limited. Here we demon-
strate that conditional deletion of hypothalamic neuropeptide
Y2 receptors can prevent ongoing bone loss in sex hormone-
deficient adultmale and femalemice.This benefit is attributable
solely to activation of an anabolic osteoblastic bone formation
response that counterbalances persistent elevation of bone
resorption, suggesting the Y2-mediated anabolic pathway to be
independent of sex hormones. Furthermore, the increase in fat
mass that typically occurs after ovariectomy is prevented by
germ line deletion of Y2 receptors, whereas in male mice body
weight and fat mass were consistently lower than wild-type
regardless of sex hormone status. Therefore, this study indicates
a role for Y2 receptors in the accumulation of adipose tissue in
the hypogonadal state and demonstrates that hypothalamic Y2
receptors constitutively restrain osteoblastic activity even in the
absence of sex hormones. The increase in bone formation after
release of this tonic inhibition suggests a promising new avenue
for osteoporosis treatment.
With age, changes in endocrine function can significantly
affect physiological processes often with detrimental effects on
health. One of the most substantial changes occurs with meno-
pause in women, with cessation of estrogen production by the
ovaries. This abrupt and dramatic decrease in estrogen produc-
tion results in a number of acute and long term physiological
effects, among the most notable of these being the loss of bone
leading to the development of osteoporosis and increased dep-
osition of white adipose tissue, contributing to an increased risk
of heart disease and associated complications.
In the adult skeleton, bonemass and strength are determined
by the multicellular process of bone remodeling, in which oste-
oclastic bone resorption is followed by osteoblastic bone for-
mation. This turnover process is normally tightly coupled,
such that the amount of bone resorbed equals the amount of
bone formed, maintaining a constant bone mass. Multiple
endocrine factors regulate turnover, in particular the sex
hormones estrogen and testosterone, which protect bone by
exerting anti-apoptotic effects on osteoblasts and pro-apo-
ptotic effects on osteoclasts, in addition to suppressing oste-
oclast activity through both direct and indirect mechanisms
(1, 2). Loss of sex hormones following menopause in women
or in hypogonadal males results in increased osteoclast
activity and loss of bone mass. Most current osteoporosis
treatments inhibit bone resorption; however, although these
treatments reduce further deterioration, they are unable to
stimulate bone formation to replace bone that has already
been lost, leaving osteoporotic patients with significantly
weakened bones and at risk of further fragility fractures.
Hence, there is a clear need to develop anabolic therapies,
which can reverse bone loss by stimulating osteoblastic bone
formation. Recent work demonstrated that disruption of a
central regulatory circuit in skeletally mature mice by con-
ditional deletion of hypothalamic neuropeptide Y2 receptors
produced a rapid bone gain, associated with increased osteo-
blast activity and bone formation (3), identifying a novel cen-
tral regulator of bonemetabolismwhile providing persuasive
evidence of the potential utility of this anabolic pathway for
osteoporosis treatment.
The Y2 receptor also has an important role in the regulation
of body weight, with Y2 receptor knock-out attenuating the
obesity syndrome of hypogonadal, leptin-deficient ob/ob mice
(4, 5). The increase in body fat mass following menopause con-
tributes to an increased risk of cardiovascular and metabolic
diseases (6, 7). This increase in adipose tissue is associated with
a corresponding increase in levels of the Y2 receptor ligand
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neuropeptide Y (NPY)3 (8, 9). Thus Y2 receptors may play an
important role in two of the major endocrine consequences of
sex hormone deficiency, bone loss and adipose accumulation.
As there are no oral selective Y2 receptor antagonists avail-
able, the therapeutic potential of Y2 receptor ablation on body
weight and bone cell functionwas investigated by using surgical
gonadectomy to induce sex steroid-deficient bone loss in male
and female mice in combination with germ line or hypotha-
lamic deletion of Y2 receptors. Our results clearly demonstrate
a protection against gonadectomy-induced changes in adipose
mass and a significant protection against further bone loss
induced by activation of the Y2-mediated central anabolic
response.
EXPERIMENTAL PROCEDURES
Generation of Germ Line and Conditional Y2 Receptor Knock-
out Mice—Animal experiments were approved by the Garvan
Institute of Medical Research Animal Research Authority and
were conducted in accordance with relevant guidelines and regu-
lations.Germ line andconditional knock-outmiceweregenerated
and genotyped as described previously (3, 10).
Gonadectomies—All mice were either sham-operated or
gonadectomized at 8 weeks of age. To determine the effect of
pre-existing Y2 receptor deletion on gonadectomy-induced
bone loss, wild-type and germ line Y2 receptor knock-out
(Y2/) mice were collected 8 weeks after gonadectomy, at 16
weeks of age. To investigate the response to activation of the
anabolic pathway following the development of bone loss,
Y2lox/lox mice were injected with adeno-associated viral vectors
(AAV-cre or AAV-empty) 8 weeks after gonadectomy, at 16
weeks of age. Thesemicewere left for 6weeks to allow the effect
of Y2 deletion to develop and were collected at 22 weeks of age,
a total of 14 weeks after gonadectomy.
Adeno-associated Virus Injection—16-Week-oldY2lox/loxmice
were anesthetized with 100 mg/kg ketamine (Mavlab, Slacks
Creek, Queensland, Australia) and 20 mg/kg xylazine (Ilium Vet-
erinary Products, Smithfield, New South Wales, Australia) and
injectedwith recombinantAAVvectors containing either the cre-
recombinase gene or an empty cassette using a stereotaxic frame
(Kopf Instruments, Tujunga, CA). Brain coordinates relative to
bregma were posterior 2.3 mm, lateral0.4 mm, ventral 5.6 mm,
corresponding to the arcuate nucleus.Onemicroliter of virus (1
1014 genomic copies/ml)was injectedbilaterally over 10minusing
a 26-gauge guide cannula and a 33-gauge injector (Plastics One,
Roanoke,VA) connected to aHamilton syringe anda syringe infu-
sion pump (World Precision Instruments, Waltham, MA). Mice
were housed individually to monitor daily food intake and body
weight.
Tissue Collection and Analysis—Mice were injected with 15
mg/kg of the fluorescent tetracycline compound calcein
(Sigma) 10 days and 3 days prior to collection. At either 16
(germ line Y2 receptor knock-outs) or 22 weeks of age (condi-
tional Y2 receptor knock-outs), mice were killed by cervical
dislocation, and trunk blood was collected for serum hormone
analysis. White adipose tissue (WAT) depots (right inguinal,
right retroperitoneal, and mesenteric) were collected and
weighed. The weight of these tissues was summed and
expressed as total white adipose tissue mass. Interscapular
brown adipose tissue (BAT)was also excised andweighed. Both
femora were excised and bisected transversely at the shaft mid-
point. The distal halves of the right femora together with lum-
bar vertebrae were fixed in 4% paraformaldehyde in phos-
phate-buffered saline and embedded, undecalcified in methyl
methacrylate (Medim-Medizinische Diagnostik, Giessen, Ger-
many) (3). 5-m sagittal sections were used to analyze and
calculate mineralized trabecular bone volume, number, and
thickness, osteoclast surface, and mineral apposition rate as
described previously (3), using either BioQuant software (R &
M Biometrics Inc., Nashville, TN) or Leica QWin analysis soft-
ware (Leica Microsystems Ltd., Heerberg, Switzerland). Radio-
immunoassay kits were used to determine serum concentra-
tions of IGF-1 (Biclone Australia PTY. Ltd., Marrickville,
Australia) and corticosterone (MP Biomedicals, Orangeburg,
NY). Osteocalcin was measured using a mouse osteocalcin EIA
kit (Biomedical Technologies Inc., Stoughton, MA).
Statistical Analysis—All data were assessed by factorial anal-
ysis of variance, followed by Fisher’s post hoc tests, using Stat-
View version 4.5 (Abacus Concepts, San Francisco). For all sta-
tistical analyses, p  0.05 was accepted as being statistically
significant.
RESULTS
Germ Line Y2 Receptor Deletion and Gonadectomy-induced
Changes in BodyWeight, Adipose, and Biochemical Parameters—
Toinvestigatewhether deletion of Y2 receptors affects gonadec-
tomy-induced changes in adipose tissue deposition, germ line
Y2/mice were assessed for changes in body weight and adi-
posity at 16 weeks of age, 8 weeks following gonadectomy.
Body weights of female sham-operated wild-type and Y2/
mice were similar, with an increase in body weight in wild-type
but not Y2/ females following ovariectomy (Fig. 1A), associ-
atedwith increased inguinal, retroperitoneal, and totalWATmass
(Fig. 1,B,D, andE), whichwas not increased in Y2/mice. Total
WATmasswas significantly lower in ovariectomized Y2/mice
compared with wild type (Fig. 1E), suggesting that germ line Y2
deletion provides resistance to the ovariectomy-associated
increase in adipose mass.
Male germ line Y2/mice were significantly lighter than
wild-type mice (Fig. 1H), with lighter inguinal, mesenteric,
retroperitoneal, and total WAT (Fig. 1, I–L) in Y2/males.
BAT mass was also significantly lower in Y2/ sham-oper-
ated males compared with wild-type (Fig. 1M), suggesting
increased thermogenesis that would also likely contribute to
reduced body weight. Orchidectomized mice were lighter
compared with sham-operated genotype-matched controls
(Fig. 1H), demonstrating that although lighter than wild-
type mice, germ line deletion of Y2 receptors does not sig-
nificantly alter the body composition changes that occur in
response to orchidectomy.
Serum concentrations of IGF-1 and osteocalcin were unaf-
fected by gonadectomy or germ line deletion of Y2 receptors in
both sexes. Serum corticosterone was significantly reduced in
3 The abbreviations used are: NPY, neuropeptide Y; WAT, white adipose tis-
sue; BAT, brown adipose tissue;MS,mineralizing surface; BFR, bone forma-
tion rate; MAR, mineral apposition rate; AAV, adeno-associated virus.
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ovariectomizedY2/ comparedwithwild-typemice (Fig. 1G),
but was significantly higher inmale Y2/mice comparedwith
wild type and in orchidectomized compared with sham-oper-
ated germ line Y2/mice (Fig. 1N), suggesting a gender-spe-
cific change in the levels and gonadectomy-induced response of
this hormone.
FIGURE 1.Germ lineY2knock-out reducesdepositionofwhite adipose tissue.A–G, femalemice. Shownare the effects of ovariectomy (OVX) andgerm line
Y2 receptor deletion on body weight (A), inguinal (B), mesenteric (C), retroperitoneal (D), total white adipose tissue (E), brown adipose tissue (F), and serum
levels of IGF-1, corticosterone, and osteocalcin (G). Deletion of Y2 receptors prevents increased body weight and white adipose tissue mass following
ovariectomy.H–N,malemice. Shown are the effects of orchidectomy (ORX) and germ line Y2 receptor deletion on bodyweight (H), inguinal (I), mesenteric (J),
retroperitoneal (K ), total white adipose tissue (L), brown adipose tissue (M), and serum levels of IGF-1, corticosterone, and osteocalcin (N). Deletion of Y2
receptors reduces bodyweight andwhite adiposemass. Asterisks indicate statistically significant differences versuswild-type equivalent operation *, p 0.05;
**, p 0.01; ***, p 0.001. Hatch marks indicate significant differences versus sham within same genotype #,0.05; ###, p 0.001; wt,wild type; BWt, body
weight.
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Germ Line Y2 Receptor Deletion and Gonadectomy-induced
Bone Loss in the Distal Femur—16-Week-old male and female
sham-operated germ line Y2/mice had significantly greater
trabecular bone volume at the distal
femur than the sham-operated wild
type (Fig. 2, A, C, and J). Gonadec-
tomy at 8 weeks of age significantly
reduced trabecular bone volume of
bothwild-type andY2/mice (Fig.
2, A, C, and J). In females, however,
despite a similar percentage reduc-
tion in bone volume in both ovariec-
tomized Y2/ and wild-type mice,
the remaining bone volume in
ovariectomized Y2/ mice was
comparable withwild-type sham lev-
els and remained significantly greater
than bone volume of ovariectomized
wild-type mice (Fig. 2C). Similarly,
trabecularnumberandthickness (Fig.
2, D and E) both remained signifi-
cantly greater in ovariectomized
Y2/ compared with wild-type
mice. Hence germ line deletion of Y2
receptors provided some protection
against ovariectomy-induced bone
loss and deterioration of bonemicro-
architecture in the distal femur.
In contrast to observations in
ovariectomized female mice, orchi-
dectomy of wild-type and Y2/
male mice abolished the difference
in trabecular bone volume between
the two genotypes (Fig. 2J) because
of reduced trabecular number and
thickness (Fig. 2, K and L).
In females, the loss of trabecular
bone volume following ovariectomy
was associated with increased oste-
oclast and mineralizing surface
(MS), consistent with the character-
istic response to estrogen deficiency
(11–14). The increased osteoclast
surface inwild-type andY2/mice
was comparable and not affected by
Y2 receptor deletion (Fig. 2F). MS, a
measure of the extent ofmineraliza-
tion, was elevated in ovariectomized
wild-type and Y2/mice, reaching
statistical significance only in wild-
type mice (Fig. 2G). Similarly, the
loss of trabecular bone volume fol-
lowing orchidectomy in male mice
was associated with significantly
increased osteoclast surface in both
genotypes (Fig. 2M). MS was ele-
vated in orchidectomized Y2/
but not wild-type mice (Fig. 2N).
Importantly, however, the elevated rate of mineral apposi-
tion (MAR), which confers the greater trabecular bone volume
in nonoperated Y2/ mice (3), was maintained following
FIGURE 2. Anabolic activity of germ line Y2 knock-out mice remains active following gonadectomy. A–I,
femalemice. Shownare thehistological analysesofdistal femur fromovariectomized (OVX)wild-typeandgermline
Y2/mice (A), andmeasurements of trabecular bone volume (BV/TV) (C), trabecular number (Tb.N) (D), trabecular
thickness (Tb.Th) (E ), osteoclast surface (Oc.S/BS) (F ), mineralizing surface (MS) (G), mineral apposition rate (H), and
bone formationrate (I).Greaterdistancebetweencalcein labels (B)demonstratesanabolicpathway ismaintained in
ovariectomized germ line Y2/mice and provides protection against ovariectomy-induced bone loss. J–P,male
mice. Shown are the measurements of trabecular bone volume of distal femur from orchidectomized (ORX) wild-
type andgerm line Y2/mice (J), trabecular number (K), trabecular thickness (L), osteoclast surface (M), mineraliz-
ing surface (N), mineral apposition rate (O), and bone formation rate (P); the anabolic pathway is maintained in
orchidectomizedgerm line Y2/mice.Asterisks indicate statistically significant differences versuswild-type equiv-
alent operation: *, p 0.05; **, p 0.01; ***, p 0.001. Hatch marks indicate significant differences versus sham
within same genotype #,0.05; ##, p 0.01; ###, p 0.001;wt,wild type.
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gonadectomy in both female andmalemice (Fig. 2,B,H, andO).
Furthermore, BFR, a measure of total osteoblast activity, was
elevated in gonadectomized Y2/mice to a level even greater
than sham-operated values (Fig. 2, I and P). Together, these
results clearly demonstrate that the Y2-associated anabolic
response persists in the absence of sex hormones in both males
and females, and the preservation of bone micro-architecture
post-ovariectomy in female Y2/mice was likely the result of
Y2-dependent anabolic activity, demonstrating this anabolic
pathway to be independent of the presence of sex hormones.
These results from germ line
Y2/mice reveal that although the
anabolic activity of the Y2 pathway
remains elevated in the absence of
sex hormones, this is not sufficient
to provide resistance to gonadecto-
my-induced bone loss. In the clinic,
however, an effective anabolic osteo-
porosis treatment must rebuild
osteopenic bone. To assess whether
activation of the Y2-mediated ana-
bolic response can reverse bone loss
that has already occurred, we uti-
lized a conditional Y2 receptor
knock-out model, using hypotha-
lamic injection of recombinant
adeno-associated viral vector con-
taining the cre-recombinase gene
(AAV-cre) to delete the Y2 receptor
gene in adult Y2lox/lox mice. Hypo-
thalamic Y2 receptors were deleted
in 16-week-old Y2lox/lox mice, 8
weeks after gonadectomy, followed
by a further 6 weeks to allow the
consequences of Y2 gene deletion to
develop. Control Y2lox/loxmicewere
injected with adeno-associated viral
vector without the transgene (AAV-
empty), therefore remaining geneti-
cally equivalent to wild-type mice.
This model, in which the anabolic
pathway is activated following the
occurrence of bone loss, is more
akin to the typical osteoporotic
patient, in whom treatment is initi-
ated after substantial bone has been
lost.
Conditional Hypothalamic Y2 Re-
ceptor Deletion and Gonadectomy-
induced Changes in Body Weight,
Adipose, and Biochemical Para-
meters—Investigation of whether
conditional activation of this central
pathway would affect gonadectomy-
induced changes in body weight
revealed that hypothalamus-specific
deletionofY2receptorshadnosignif-
icant effect on body weight or food
intake in gonadectomized female or male mice (Fig. 3, A and H,
and data not shown).
In females, fat pad weights from ovariectomized conditional
Y2/mice were similar to sham-operated controls (Fig. 3, B–F).
As WAT mass would be expected to increase following ovariec-
tomy prior to the deletion of Y2 receptors, these findings suggest
that similar to germ line deletion, hypothalamic deletion of Y2
receptors caused a decrease inWATmass.
In males, BAT was similarly reduced in both orchidecto-
mized models (Fig. 3M). However, in contrast to orchidecto-
FIGURE 3. Effect of hypothalamic Y2 receptor deletion on white adipose tissue deposition. A–G, female
mice. Shown are the effects of ovariectomy (OVX) and conditional deletion of hypothalamic Y2 receptors on
body weight (BWt) (A), inguinal (B), mesenteric (C), retroperitoneal (D), total white adipose tissue (E), brown
adipose tissue (F), and serum levels of IGF-1, corticosterone, and osteocalcin (G); deletion of hypothalamic Y2
receptors reduces white adipose tissue mass to sham levels. H–N, male mice. Shown are the effects of orchi-
dectomy (ORX) and conditional deletion of hypothalamic Y2 receptors on body weight (H), inguinal (I), mes-
enteric (J), retroperitoneal (K), totalwhite adipose tissue (L), brownadipose tissue (M), and serum levels of IGF-1,
corticosterone, and osteocalcin (N); deletion of hypothalamic Y2 receptors does not affect body weight and
increases white adipose mass compared with orchidectomized AAV-empty controls. Asterisks indicate statis-
tically significant differences versus sham Cre Y2lox/lox: *, p  0.05; **, p  0.01; ***, p  0.001. Hatch marks
indicate significant differences versus Gx Empty Y2lox/lox; #,0.05.
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mized germ line Y2/ mice, which were significantly lighter
and less fat than similarly operated wild-typemice, orchidecto-
mized conditional Y2/ mice had increased mesenteric, ret-
roperitoneal, and total WAT mass compared with orchidecto-
mized AAV-empty recipient mice (Fig. 3, J–L), suggesting that
populations of Y2 receptors other than those in the hypothala-
mus, possibly peripheral, are impor-
tant for sex hormone-regulated fat
deposition in male mice.
Conditional deletion of Y2 recep-
tors did not affect serum levels of
IGF-1, corticosterone, or osteocal-
cin, although corticosterone was
elevated in both gonadectomized
groups compared with conditional
Y2/ sham-operated mice, with
the difference reaching significance
only in AAV-empty recipient mice
(Fig. 3, G and N).
Conditional Hypothalamic Y2
Receptor Deletion and Gonadecto-
my-induced Bone Loss in the Distal
Femur—Six weeks following condi-
tional deletion of hypothalamic Y2
receptors in previously gonadecto-
mized female and male Y2lox/lox
mice, trabecular bone volume at the
distal femurwas 2-fold greater com-
pared with bone volume in gona-
dectomized Y2lox/lox AAV-empty
recipient mice (Fig. 4, A, B, and I).
This difference in bone volume was
due to a significantly greater trabec-
ular number in male mice (Fig. 4J),
with significantly greater trabecular
thickness in both female and male
mice (Fig. 4, D and K), demonstrat-
ing that conditional deletion of
hypothalamic Y2 receptors can sig-
nificantly improve outcome fol-
lowing gonadectomy-induced bone
loss, with marked protection of
bone mass and microarchitecture.
Osteoclast surface was signifi-
cantly increased by gonadectomy in
both groups (AAV-cre and AAV-
empty) compared with sham-oper-
ated AAV-cre recipient mice (Fig. 4,
E and L), indicating that as in the
germ line Y2 knock-outs, condi-
tional deletion of hypothalamic Y2
receptors did not inhibit gonadec-
tomy-induced increases in bone
resorption at this skeletal site. MS
was unaffected by surgery or by con-
ditional deletion of Y2 receptors
(Fig. 4, F andM).
Importantly, and consistent with
our findings in germ line Y2/ mice, MAR was again signifi-
cantly elevated in both sham-operated and gonadectomized
mice lacking hypothalamic Y2 receptors, compared with AAV-
empty controls (Fig. 4, G and N). A similar pattern was also
observed for BFR (Fig. 4, H and O), and together they demon-
strate that despite persistent high resorptive activity, condi-
FIGURE 4. Conditional deletion of hypothalamic Y2 receptors activates an anabolic response and pre-
vents gonadectomy-induced bone loss in the distal femur. A–H, female mice. Shown are the histological
analyses of distal femur from ovariectomized (OVX) Y2lox/lox mice receiving either AAV-empty or AAV-cre (A),
and measurements of trabecular bone volume (BV/TV) (B), trabecular number (Tb.N) (C), trabecular thickness
(Tb.Th) (D), osteoclast surface (Oc.S/BS) (E), mineralizing surface (F), mineral apposition rate (G), and bone
formation rate (H); greater mineral apposition rate demonstrates the anabolic pathway is active and prevents
further ovariectomy-induced bone loss despite elevated osteoclast surface. I–O, male mice. Shown are the
measurements of trabecular bone volume of distal femur fromorchidectomized Y2lox/lox mice receiving either
AAV-empty or AAV-cre (I), trabecular number (J), trabecular thickness (K), osteoclast surface (L), mineralizing
surface (M), mineral apposition rate (N), and bone formation rate (O); greatermineral apposition rate and bone
formation rate demonstrate the anabolic pathway is active and prevents further orchidectomy-induced bone
loss despite elevated osteoclast surface. Asterisks indicate statistically significant differences versus sham Cre
Y2lox/lox: *, p 0.05; **, p 0.01; ***, p 0.001. Hatch marks indicate significant differences versus Gx Empty
Y2lox/lox: #,0.05; ##, p 0.01; ###, p 0.001.
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tional deletion of hypothalamic Y2 receptors can prevent fur-
ther gonadectomy-induced bone loss in both female and male
mice through activation of a central Y2-mediated bone anabolic
pathway. Furthermore, this anabolic response was strong
enough to produce a difference in bone mass compared with
AAV-empty recipient mice within just 6 weeks, with substan-
tial benefits to trabecular microarchitecture.
Conditional Hypothalamic Y2 Receptor Deletion and Gona-
dectomy-induced Bone Loss of the Vertebrae and Femur—Anal-
ysis of lumbar vertebrae revealed a pattern similar to the distal
femur, with conditional deletion of hypothalamic Y2 receptors
in gonadectomized Y2lox/lox mice significantly elevating trabe-
cular bone volume compared with AAV-empty controls (Fig. 5,
A, B, and E). Osteoclast surface was significantly increased in
gonadectomized compared with sham-operated male but not
female mice regardless of knock-out status (Fig. 5, C and F).
Importantly, as seen in the distal femur, the greater bone vol-
ume after hypothalamus-specific Y2 knock-out in gonadecto-
mized mice could be attributed to a significantly greater MAR
compared with gonadectomized AAV-empty recipient mice of
both genders (Fig. 5, D and G). This
is the first demonstration that the
bone anabolic response elicited by
deletion of hypothalamic Y2 recep-
tors is similar in different skeletal
regions and indicates a generalized
anabolic activity in bone.
Comparison with the effects of
gonadectomy in wild-type mice
establishes the consequences of
deleting hypothalamic Y2 receptors
in adult mice after the occurrence
of significant gonadectomy-induced
bone loss in the distal femur. In
wild-typemice, trabecular bone vol-
ume was reduced by 50% in the
distal femur 8 weeks after gonadec-
tomy in either sex (Fig. 6, A and D).
This reduction of bone volume con-
tinued to 14 weeks post-operation
in AAV-empty recipient mice.
Importantly, this latter phase of
bone loss was blocked in mice in
which hypothalamic Y2 receptors
were deleted 6weeks prior to collec-
tion, leaving these mice with twice
the amount of bone volume com-
pared with control AAV-empty
recipient mice (Fig. 6, A and D).
Osteoclast surface was elevated in
all gonadectomy groups compared
with sham-operated wild-type mice
(Fig. 6,B andE). However,MARwas
elevated only in mice deficient in
hypothalamic Y2 receptors (Fig. 6,C
and F), providing the first demon-
stration that the central Y2-associ-
ated anabolic response can over-
come elevated bone resorption induced by sex hormone
deficiency and effectively prevent further bone loss.
DISCUSSION
This study clearly demonstrates that hypothalamus-specific
deletion of Y2 receptors prevents bone loss induced by defi-
ciency of gonadal hormones in both male and female mice.
Furthermore, our study demonstrates that germ line deletion of
Y2 receptors prevents the elevation in WAT mass following
ovariectomy, with differences between the regulation of
WATmass in orchidectomized male germ line and hypotha-
lamic Y2/ mice suggesting that Y2 receptors other than
those located in the hypothalamus may be responsible for
this effect. Together these findings are indicative of site
specificity or alternative pathways regulated by Y2 receptors
controlling bone formation and the deposition of WAT in
the absence of sex hormones.
Sex hormones play an important role in regulating body fat,
with levels of intra-abdominal fat increased up to 49% in post-
menopausal compared with pre-menopausal women (15). Our
FIGURE 5. Conditional deletion of hypothalamic Y2 receptors activates an anabolic response and pre-
vents gonadectomy-induced bone loss in the vertebrae. A–D, female mice. Shown are the histological
analyses of lumbar vertebrae from ovariectomized (OVX) Y2lox/lox mice receiving either AAV-empty or AAV-cre
(A), and measurements of trabecular bone volume (BV/TV) (B), osteoclast surface (Oc.S/BS) (C), and mineral
apposition rate (D); greater mineral apposition rate demonstrates anabolic pathway is active in the lumbar
vertebrae andprevents further ovariectomy-inducedbone loss. E–G,malemice. Shown are themeasurements
of trabecular bone volume of lumbar vertebrae from orchidectomized Y2lox/lox mice receiving either AAV-
empty or AAV-cre (E), osteoclast surface (F), and mineral apposition rate (G); greater mineral apposition rate
demonstrates anabolic pathway is active in the lumbar vertebrae and prevents further orchidectomy-induced
bone loss despite elevated osteoclast surface. Asterisks indicate statistically significant differences versus sham
CreY2lox/lox: *,p0.05; **,p0.01; ***,p0.001.Hatchmarks indicate significant differences versusGxEmpty
Y2lox/lox, #,0.05; ##, p 0.01; ###, p 0.001.
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study also demonstrates a significant increase inWAT content
in ovariectomized wild-type mice but not germ line Y2/
mice. Studies in humans (16) and rodents (8, 9) have established
a potential role for elevated NPY in the accumulation of WAT
that occurs with menopause. Our findings are supportive of a
role for the NPY system in the regulation of WAT content fol-
lowing the removal of gonadal hormones and strongly suggest a
role for Y2 receptors in the control of this process.
These studies also demonstrate that whereas constitutive
activation of the bone anabolic response in germ line Y2/
mice does not entirely protect against sex hormone-deficient
bone loss, selective activation of only the hypothalamic Y2-as-
sociated bone formation response following the occurrence of
significant hypogonadal bone loss effectively prevents further
bone loss. Of particular interest, this prevention of bone loss
occurred despite elevated bone resorption and thus is specifi-
cally attributable to a Y2-associated anabolic response of osteo-
blastic cells. The end result was a doubling of trabecular bone
volume in the distal femur and significantly increased bone
mass in the lumbar vertebrae of gonadectomized mice lacking
hypothalamic Y2 receptors compared with their counterparts
with an intact Y2 receptor gene.
Interestingly, maximal activation of the bone formation
pathway was achieved equally by deletion of germ line and
hypothalamic Y2 receptors, demonstrating this pathway to be
centrally mediated. A recent study using pseudorabies virus-
based transneuronal tracing to map trans-synaptically con-
nected neurons from rat bone provided direct evidence that
nerve fibers within bone tissue are
under the control of synaptic trans-
mission from the hypothalamus
(17), providing a putative mecha-
nism by which deletion of hypotha-
lamic Y2 receptors can affect osteo-
blastic activity.
Notably, the marked improve-
ment in bone volume seen in this
study occurred within just 6 weeks
of hypothalamic Y2 receptor dele-
tion, a clear demonstration of the
potency of this central anabolic
pathway, providing crucial evidence
that this pathway may be a suitable
target to increase bone mass in
osteoporotic patients, who are usu-
ally diagnosed only after significant
bone loss has already occurred.
It is interesting to note that mice
with a constitutively active bone
formation response because of germ
line Y2 knock-out were not more
resistant to gonadectomy-induced
bone loss, whereas activation of the
Y2 anabolic response in adults pre-
vented any further bone loss. There
are a number of possible explana-
tions for this finding. Osteoclast
surface was reduced at the 22-week
time point in ovariectomized conditional Y2/ female mice
compared with 16-week-old ovariectomized germ line Y2/
mice. This finding is not unexpected as the gonadectomy-in-
duced increase in resorption is an acute response, which rapidly
diminishes (13, 14). MAR was also higher in orchidectomized
conditional Y2/male mice compared with germ line knock-
outs, suggesting that a greater osteoblastic response in the con-
ditional knock-outsmay be responsible for the protective effect
on orchidectomy-induced bone loss. As the anabolic bone for-
mation response was actually active in both male and female
gonadectomized germ line Y2/ mice, as evidenced by a
greater MAR and BFR, it is possible that the only reason why a
protective effect was observed in the conditional knock-outs
and not in the germ lines was a longer time post-operation,
allowing the anabolic response to overcome the acute increase
in resorption.
Higher body weight is associated with higher bone mineral
density in human studies (18). The data presented here, how-
ever, show that the increased bone volume of gonadectomized
Y2 receptor knock-out mice was not because of increased body
weight, as body weight and fat mass were actually reduced in
germ line Y2 knock-out mice and unchanged in conditional
knock-out mice. IGF-1 is known to affect bone growth and
turnover (19), and Y2 receptors regulate serum IGF-1 concen-
trations under conditions of elevatedNPY-ergic expression (4).
However, serum IGF-1 concentrations were unaffected by Y2
receptor deletion. Elevated corticosterone decreases bone
mass; however, serum corticosterone also cannot explain the
FIGURE 6. Activation of central Y2 receptor-associated anabolic response halts further bone loss. A–C,
female mice; D–F, male mice. Shown are the comparisons of the effects of gonadectomy (Gx) after 8 and 14
weeks on bone loss in the distal femur of wild-type and conditional Y2/mice, respectively. Shown are the
trabecular bone volumes (BV/TV) (A andD), osteoclast surfaces (Oc.S/BS) (B and E), andmineral apposition rates
(C and F); conditional deletion of hypothalamic Y2 receptors 8 weeks after gonadectomy completely prevents
further bone loss in both female andmalemice, because of activation of a central anabolic response. Asterisks
indicate statistically significant differences versus sham-operated wild type: *, p 0.05; **, p 0.01; ***, p
0.001. Hatch marks indicate significant differences versus gonadectomy Empty Y2lox/lox: #,0.05; ##, p 0.01;
###, p 0.001.
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bone differences observed in these mice. Ovariectomized wild-
type mice had greater serum corticosterone compared with
ovariectomized Y2/ mice, which could possibly influence
bone volume; however, corticosterone was unchanged in
sham-operated Y2/ compared with wild-type mice sug-
gesting this is unlikely. Moreover, serum corticosterone was
actually greater in germ line Y2/ mice compared with
wild-type, which would be expected to produce a decrease
rather than the observed increase in bone volume. In condi-
tional Y2/mice, serum corticosterone levels in both male
and female mice were similar between both gonadectomy
groups, again arguing against changes in corticosterone lev-
els being responsible for the bone changes.
In osteoporosis, excess osteoclastic resorption results in deep
resorption pits, causing trabecular perforation and loss of tra-
becular structures. A reduction in bone formation contributes
to the deterioration of bone microarchitecture, as lost bone
material is not adequately replaced (20–23). Anabolic treat-
ments to balance out excess osteoclastic activity are therefore
essential. In this study, conditional deletion of hypothalamic Y2
receptors in gonadectomized female and male adult mice
resulted in significantly greater trabecular thickness compared
withAAV-empty recipientmice and,most importantly, greater
trabecular number in orchidectomized conditional knock-out
mice compared with AAV-empty controls. A similar but non-
significant trend was noted in female mice. These data suggest
that the Y2 receptor-associated anabolic pathway not only
improves total bone mass but also results in a beneficial micro-
architectural outcome compared with gonadectomized wild-
type mice.
These beneficial effects on bone volume and microarchitec-
ture occurred in the face of elevated resorption. It is possible
that even more bone mass could be replaced over a longer
period of time after conditional deletion of hypothalamic Y2
receptors. It will also be important to investigate whether con-
current or sequential administration of an anti-resorptive treat-
ment in combination with Y2 receptor deletion can allow a
more effective anabolic response. Interestingly, recent studies
of co-administration of the only available anabolic therapy, par-
athyroid hormone-(1–34) with anti-resorptive bisphospho-
nate, indicated that the anti-resorptive treatment may reduce
the anabolic potential of parathyroid hormone (24, 25).
With the aging population, it is predicted that an increase in
the incidence of osteoporotic fractures will be a major problem
(26). The studies presented here demonstrate that inactivation
of hypothalamic Y2 receptor signaling can prevent continued
loss of bone by stimulating bone formation in gonadectomized
adult mice. Furthermore, germ line deletion of Y2 receptors
prevented the accumulation inWAT in ovariectomized female
mice and reducedWATmass inmalemice. These results high-
light the potential of this promising new avenue for the treat-
ment of osteoporosis and obesity. Currently, there are no orally
available Y2 receptor-specific antagonists. Our study empha-
sizes the need to develop such Y2 receptor-specific antagonists
with the promising potential for treatment of excess fat depo-
sition and bone degenerative conditions.
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The plasmid used to express FLAG-hSnf7N (residues 1–116) in this
paper had an unintended missense mutation changing serine at residue
2 to cysteine. We found that this cysteine was palmitoylated. Changing
it back to serine decreased the amount of hSnf7N associated withmem-
branes from all for the mutant fragment containing cysteine to approx-
imately half for the wild-type fragment containing serine. The images of
FLAG-hSnf7N in Figs. 7B and 8 represent average cells expressing
mutant (Cys-2) hSnf7N, whereas for wild-type (Ser-2) hSnf7N, these
images correspond to cells expressing high levels of protein. All other
plasmids are as indicated, and the conclusions of the paper remain
unchanged.
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PAGE 28385:
Due to an inadvertent error, the wrong image was presented in Fig.
4C. Fig. 4C should appear as shown below. The figure legend and text
remain unchanged.
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The concentration of a drug that was employed, adenosine dialde-
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reverts gonadectomy-induced bone loss in adult mice.
Susan J. Allison, Paul Baldock, Amanda Sainsbury, Ronaldo Enriquez,
Nicola J. Lee, En-Ju Deborah Lin, Matthias Klugmann, Matthew During,
John A. Eisman, Mei Li, Lydia C. Pan, Herbert Herzog, and Edith M. Gardiner
PAGE 23436:
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PAGE 31554:
Column 2, first line: The concentrations should read “(4.0 M) or
hemin (3.5 M). . .”
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In Fig. 5, panel D was inadvertently omitted and is shown below. The figure legend is correct as it appears.
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